肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2012年
7期
454-456
,共3页
庞敏%任国华%孙亚红%何伟娜%安玉姬%辛江泽%张卫华%宋鹏远%盛立军
龐敏%任國華%孫亞紅%何偉娜%安玉姬%辛江澤%張衛華%宋鵬遠%盛立軍
방민%임국화%손아홍%하위나%안옥희%신강택%장위화%송붕원%성립군
消化道肿瘤%尼妥珠单抗%抗肿瘤联合化疗方案
消化道腫瘤%尼妥珠單抗%抗腫瘤聯閤化療方案
소화도종류%니타주단항%항종류연합화료방안
Digestive system neoplasms%Nimotuzumab%Antineoplastic combined chemotherapy protocols
目的 观察尼妥珠单抗联合化疗治疗晚期消化道肿瘤的近期疗效及患者不良反应.方法 观察组:22例确诊的晚期消化道肿瘤患者,其中食管癌10例,胃癌6例,胰腺癌4例,胆管癌2例.给予尼妥珠单抗联合化疗治疗,尼妥珠单抗每周给予200 mg,至少完成6周.对照组:21例患者,其中食管癌10例,胃癌6例,胰腺癌3例,胆管癌2例,应用尼妥珠单抗治疗至少6周.结果 观察组有效率(RR)31.8％(7/22),疾病控制率(DCR)72.7 ％(16/22),对照组RR 14.3％(3/21),DCR 42.8％(9/21),两组间DCR及QOL改善比较差异有统计学意义(x2=3.939,x2=4.250,均P＜0.05).在RR及主要不良反应方面两组的差异无统计学意义.结论 尼妥珠单抗联合化疗治疗晚期消化道肿瘤疗效较好,可以提高疾病控制率,不良反应可耐受,生活质量得到改善.
目的 觀察尼妥珠單抗聯閤化療治療晚期消化道腫瘤的近期療效及患者不良反應.方法 觀察組:22例確診的晚期消化道腫瘤患者,其中食管癌10例,胃癌6例,胰腺癌4例,膽管癌2例.給予尼妥珠單抗聯閤化療治療,尼妥珠單抗每週給予200 mg,至少完成6週.對照組:21例患者,其中食管癌10例,胃癌6例,胰腺癌3例,膽管癌2例,應用尼妥珠單抗治療至少6週.結果 觀察組有效率(RR)31.8％(7/22),疾病控製率(DCR)72.7 ％(16/22),對照組RR 14.3％(3/21),DCR 42.8％(9/21),兩組間DCR及QOL改善比較差異有統計學意義(x2=3.939,x2=4.250,均P＜0.05).在RR及主要不良反應方麵兩組的差異無統計學意義.結論 尼妥珠單抗聯閤化療治療晚期消化道腫瘤療效較好,可以提高疾病控製率,不良反應可耐受,生活質量得到改善.
목적 관찰니타주단항연합화료치료만기소화도종류적근기료효급환자불량반응.방법 관찰조:22례학진적만기소화도종류환자,기중식관암10례,위암6례,이선암4례,담관암2례.급여니타주단항연합화료치료,니타주단항매주급여200 mg,지소완성6주.대조조:21례환자,기중식관암10례,위암6례,이선암3례,담관암2례,응용니타주단항치료지소6주.결과 관찰조유효솔(RR)31.8％(7/22),질병공제솔(DCR)72.7 ％(16/22),대조조RR 14.3％(3/21),DCR 42.8％(9/21),량조간DCR급QOL개선비교차이유통계학의의(x2=3.939,x2=4.250,균P＜0.05).재RR급주요불량반응방면량조적차이무통계학의의.결론 니타주단항연합화료치료만기소화도종류료효교호,가이제고질병공제솔,불량반응가내수,생활질량득도개선.
Objective To explore the efficacy and toxicity of nimotuzumab plus chemotherapy in the treatment of metastatic gastrointestinal tumor. Methods Observation group 22 patients with metastatic gastrointestinal tumor with confirmed diagnosis,were treated with nimotuzumab in combination chemotherapy.Nimotuzumab was given 200 mg weekly for at least six weeks. Control group 21 patients with metastatic gastrointestinal tumor with confirmed diagnosis were treated with only chemotherapy. Results The effects of observation group could be observed in 22 patients, the rate of response (RR) was 31.8％ (7/22), and the disease control rate (DCR) was 72.7 ％ (16/22).QOL was improved.The effects of observation group could be observed in 21 patients,RR was 14.3 ％ (3/21),and the disease control rate was 42.8 ％ (19/21).DCR and QOL improvements were statistically significant different between the two groups.(x2=3.939,x2=4.250,P＜0.05).The two groups had no significant difference in RR and toxicity. Conclusion Nimotuzumab in combination with chemotherapy is effective and can improve the disease control rate, toxicity, tolerance,quality of life.
